DRMA Stock Analysis: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$1.17
-0.01 (-0.85%)
▼
5d:
-11.36%
30d:
-15.22%
90d:
-14.6%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 12, 2026
8d
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: DRMA is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: DRMA is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $1.17, which is considered oversold relative to its 30-day fair value range of $1.22 to $1.36.
Technical Outlook: Technically, DRMA is showing sideways momentum. The price is currently testing key support at $1.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+241.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DRMA is showing sideways momentum. The price is currently testing key support at $1.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+241.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.22 -
$1.36
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 241.9% below Wall St target ($4.00)
- WARNING: Recommendation downgraded due to -11.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.22 -
$1.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.15
Resistance Level
$1.40
Current Trend
Sideways
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.77
Wall Street Target
$4.00
(+241.9%)
Share & Embed Analysis
Last updated: August 02, 2026 7:49 PM ET
Data refreshes hourly during market hours. Next update: 8:49 PM
Data refreshes hourly during market hours. Next update: 8:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Munera Maria E Bedoya-To…
BUY
1000 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
